Requires group and individual health plans to cover selected insulin products without a deductible and cap patient costs at the lesser of $35 or 25 percent of the net price per 30-day supply, beginning in 2028.

• Starting January 1, 2028, group and individual health plans must cover selected insulin products with no deductible and cap cost-sharing at the lesser of $35 or 25 percent of the net price per 30-day supply.
• Plans may not require prior authorization or other medical management for selected insulin products, except for clinical safety reasons, reasonable quantity limits, or as the Secretary specifies.
• Catastrophic plans must cover selected insulin products before the enrollee reaches the annual cost-sharing limit.
• Creates a 5-year pilot giving grants to 10 states to help uninsured people obtain insulin, authorizing $100 million for fiscal year 2027, and authorizes $2 million per year for fiscal years 2027 through 2032 for an insulin resource center and hotline.
• Directs the Government Accountability Office to study uninsured insulin users, lets the FDA expedite review of certain competitive biosimilars, and sets a 180-day window for citizen petitions that seek to delay generic or biosimilar approvals.

• Health, Education, Labor, and Pensions Committee (Senate)

Health